HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Correspondence: Submit a response Alert me when this article is cited Alert me when Correspondence are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sanders, D. B. Articles by Edwards, L. J. Search for Related Content PubMed PubMed Citation Articles by Sanders, D. B. Articles by Edwards, L. J.

A randomized trial of 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome

From the Department of Medicine, Duke University Medical Center, Durham, NC.

Address correspondence and reprint requests to Dr. Donald B. Sanders, DUMC-3403, Durham, NC 27710.

OBJECTIVES: The authors report the results of a prospective, placebo-controlled, randomized study to evaluate the effectiveness of 3,4-diaminopyridine (DAP) in patients with Lambert-Eaton myasthenic syndrome (LEMS) and to determine the acute and long-term side effects of DAP.

METHODS: Twenty-six patients with LEMS completed a two-arm parallel treatment protocol in which DAP, 20 mg three times daily, or placebo was given blindly for 6 days, and a quantitative examination of muscle strength (the quantitative myasthenia gravis [QMG] score) was used as the primary measure of efficacy. After the blinded study, patients were given open-label DAP and monitored for side effects as long as there was symptomatic improvement.

RESULTS: Twelve patients took DAP, and 14 took placebo. There was no difference in the age of LEMS onset, gender distribution, incidence of lung cancer, or baseline muscle strength between the patients who were randomly assigned to receive placebo and those randomly assigned to DAP. Statistical analysis using the Wilcoxon’s rank sum test demonstrated that patients who received DAP had a significantly greater improvement in the QMG score and in the summated amplitude of compound muscle action potentials recorded from three sentinel limb muscles. All but one LEMS patient had significant symptomatic improvement from subsequent open-label DAP. Side effects of DAP were negligible, consisting of perioral and digital paresthesia. Laboratory measurements demonstrated no evidence of toxicity affecting liver, renal, hematologic, endocrinologic, encephalographic, or electrocardiologic function acutely or after 6 months of open-label DAP.

CONCLUSIONS: This study corroborates previous studies and many years of clinical experience showing that DAP is an effective and safe treatment for LEMS.

Key words: Lambert-Eaton myasthenic syndrome—3—4-Diaminopyridine—Neuromuscular transmission disorders

This article has been cited by other articles:

				M. Martina, A. E. Metz, and B. P. Bean Voltage-Dependent Potassium Currents During Fast Spikes of Rat Cerebellar Purkinje Neurons: Inhibition by BDS-I Toxin J Neurophysiol, January 1, 2007; 97(1): 563 - 571. [Abstract] [Full Text] [PDF]

				J. W. de Beukelaar and P. A. S. Smitt Managing paraneoplastic neurological disorders. Oncologist, March 1, 2006; 11(3): 292 - 305. [Abstract] [Full Text] [PDF]

				M. Strupp, R. Kalla, T. Freilinger, M. Dichgans, and T. Brandt Dysfunction of the brain calcium channel CaV2.1 in absence epilepsy and episodic ataxia--a comment Brain, June 1, 2005; 128(6): E32 - E32. [Full Text] [PDF]

				E. S. Wachman, R. E. Poage, J. R. Stiles, D. L. Farkas, and S. D. Meriney Spatial Distribution of Calcium Entry Evoked by Single Action Potentials within the Presynaptic Active Zone J. Neurosci., March 24, 2004; 24(12): 2877 - 2885. [Abstract] [Full Text] [PDF]

				M. Strupp, O. Schuler, S. Krafczyk, K. Jahn, F. Schautzer, U. Buttner, and T. Brandt Treatment of downbeat nystagmus with 3,4-diaminopyridine: A placebo-controlled study Neurology, July 22, 2003; 61(2): 165 - 170. [Abstract] [Full Text] [PDF]

				M. K. Boettger, S. Till, M. X. Chen, U. Anand, W. R. Otto, C. Plumpton, D. J. Trezise, S. N. Tate, C. Bountra, K. Coward, et al. Calcium-activated potassium channel SK1- and IK1-like immunoreactivity in injured human sensory neurones and its regulation by neurotrophic factors Brain, February 1, 2002; 125(2): 252 - 263. [Abstract] [Full Text] [PDF]

				R. W. Tim, J. M. Massey, and D. B. Sanders Lambert-Eaton myasthenic syndrome: Electrodiagnostic findings and response to treatment Neurology, June 13, 2000; 54(11): 2176 - 2178. [Abstract] [Full Text] [PDF]